首页> 美国卫生研究院文献>Therapeutic Hypothermia and Temperature Management >Precise Control of Target Temperature Using N6-Cyclohexyladenosine and Real-Time Control of Surface Temperature
【2h】

Precise Control of Target Temperature Using N6-Cyclohexyladenosine and Real-Time Control of Surface Temperature

机译:使用N6-环己基腺苷精确控制目标温度并实时控制表面温度

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Targeted temperature management is standard of care for cardiac arrest and is in clinical trials for stroke. N6-cyclohexyladenosine (CHA), an A1 adenosine receptor (A1AR) agonist, inhibits thermogenesis and induces onset of hibernation in hibernating species. Despite promising thermolytic efficacy of CHA, prior work has failed to achieve and maintain a prescribed target core body temperature (Tb) between 32°C and 34°C for 24 hours. We instrumented Sprague–Dawley rats (n = 19) with indwelling arterial and venous cannulae and a transmitter for monitoring Tb and ECG, then administered CHA via continuous IV infusion or intraperitoneal (IP) injection. In the first experiment (n = 11), we modulated ambient temperature and increased the dose of CHA in an attempt to manage Tb. In the second experiment (n = 8), we administered CHA (0.25 mg/[kg·h]) via continuous IV infusion and modulated cage surface temperature to control Tb. We rewarmed animals by increasing surface temperature at 1°C h−1 and discontinued CHA after Tb reached 36.5°C. Tb, brain temperature (Tbrain), heart rate, blood gas, and electrolytes were also monitored. Results show that titrating dose to adjust for individual variation in response to CHA led to tolerance and failed to manage a prescribed Tb. Starting with a dose (0.25 mg/[kg·h]) and modulating surface temperature to prevent overcooling proved to be an effective means to achieve and maintain Tb between 32°C and 34°C for 24 hours. Increasing surface temperature to 37°C during CHA administration brought Tb back to normothermic levels. All animals treated in this way rewarmed without incident. During the initiation of cooling, we observed bradycardia within 30 minutes of the start of IV infusion, transient hyperglycemia, and a mild hypercapnia; the latter normalized via metabolic compensation. In conclusion, we describe an intravenous delivery protocol for CHA at 0.25 mg/(kg·h) that, when coupled with conductive cooling, achieves and maintains a prescribed and consistent target Tb between 32°C and 34°C for 24 hours.
机译:定向温度管理是心脏骤停的护理标准,并且正在中风的临床试验中。 N 6 -环己基腺苷(CHA)是一种A1腺苷受体(A1AR)激动剂,可抑制生热作用并诱导冬眠物种冬眠。尽管CHA具有良好的热分解功效,但现有工作未能在32°C至34°C的温度范围内达到并维持规定的目标核心体温(Tb)24小时。我们对Sprague-Dawley大鼠(n = 19)留置了动脉和静脉插管,并用变送器监测Tb和ECG,然后通过连续IV输注或腹膜内(IP)注射给予CHA。在第一个实验中(n = 11),我们调节环境温度并增加CHA的剂量,以尝试控制Tb。在第二个实验中(n = 8),我们通过连续静脉输注和调节笼表面温度来控制CHA来给予CHA(0.25 [mg / [kg·h])。我们通过在1°C h -1 升高表面温度使动物变热,并在Tb达到36.5°C后停止CHA。还监测Tb,脑温(Tbrain),心率,血气和电解质。结果表明,针对CHA的个体变化调整滴定剂量会导致耐受,并且无法控制规定的Tb。从剂量(0.25μmg/ [kg·h])开始,调节表面温度以防止过冷,是达到并保持Tb在32°C至34°C之间24小时的有效手段。在使用CHA的过程中,将表面温度提高到37°C,使Tb恢复到常温水平。以这种方式治疗的所有动物都可以恢复体温,而不会发生任何事故。在开始冷却过程中,我们在静脉输注开始30分钟内观察到心动过缓,短暂性高血糖和轻度高碳酸血症。后者通过代谢补偿标准化。总之,我们描述了CHA以0.25 deliverymg /(kg·h)的静脉内给药方案,当与传导冷却相结合时,可在32°C至34°C之间达到并保持规定的目标Tb 24小时并保持一致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号